Autopsy report · NCT04835168

Safety and Pharmacokinetics of Orodispersible BT-11 in Active Eosinophilic Esophagitis

“The closure of the study is driven by the decision to redesign the study protocol for future studies.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

NImmune Biopharma

Sponsor type

Industry

Conditions

Eosinophilic Esophagitis

Interventions

BT-11 low; BT-11 high; Placebo

Participants

0

Trials that died the same way

• Effects of Whole Food, Plant-Based Nutrition on Chronic Kidney Disease With Proteinuria
  “Substantially redesigning study protocol and opening a new study in the future.” (81% match in meaning)
• Estimate Serum Oxytocin PD Range in the Periphery
  “Study will be replaced by a revised study protocol” (79% match in meaning)
• OsseoFit™ Prospective Data Collection
  “Planning new study protocol” (73% match in meaning)
• Treatment of Balance Disorders in Parkinson's Patients Using SpotOn Balance Glasses
  “The study protocol needed to be modified” (72% match in meaning)
• A Study in Patients With Advanced Parkinson's Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion Versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension
  “Decision to change the study design” (68% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.